Asahi Kasei’s Hovilpri is now approved for treating lesions caused by herpes simplex virus infection. This daily pill came from the $919 million acquisition of AiCuris Anti-Infective Cures.
The post Asahi Kasei Acquisition Pays Off With FDA Approval for Novel Herpes Drug appeared first on MedCity News.
